Why Investors Shouldn't Be Surprised By Atrys Health, S.A.'s (BME:ATRY) P/S

When close to half the companies in the Healthcare industry in Spain have price-to-sales ratios (or "P/S") below 0.6x, you may consider Atrys Health, S.A. (BME:ATRY) as a stock to potentially avoid with its 1.2x P/S ratio. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the elevated P/S.

View our latest analysis for Atrys Health

What Does Atrys Health's Recent Performance Look Like?

Recent times have been advantageous for Atrys Health as its revenues have been rising faster than most other companies. It seems that many are expecting the strong revenue performance to persist, which has raised the P/S. However, if this isn't the case, investors might get caught out paying too much for the stock.

Keen to find out how analysts think Atrys Health's future stacks up against the industry? In that case, our free report is a great place to start.

How Is Atrys Health's Revenue Growth Trending?

In order to justify its P/S ratio, Atrys Health would need to produce impressive growth in excess of the industry.

Taking a look back first, we see that the company grew revenue by an impressive 19% last year. The strong recent performance means it was also able to grow revenue by 213% in total over the last three years. So we can start by confirming that the company has done a great job of growing revenue over that time.

Turning to the outlook, the next three years should generate growth of 7.4% per annum as estimated by the three analysts watching the company. With the industry only predicted to deliver 5.0% each year, the company is positioned for a stronger revenue result.

With this in mind, it's not hard to understand why Atrys Health's P/S is high relative to its industry peers. Apparently shareholders aren't keen to offload something that is potentially eyeing a more prosperous future.

What Does Atrys Health's P/S Mean For Investors?

Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

We've established that Atrys Health maintains its high P/S on the strength of its forecasted revenue growth being higher than the the rest of the Healthcare industry, as expected. Right now shareholders are comfortable with the P/S as they are quite confident future revenues aren't under threat. Unless these conditions change, they will continue to provide strong support to the share price.

Having said that, be aware Atrys Health is showing 2 warning signs in our investment analysis, you should know about.

If these risks are making you reconsider your opinion on Atrys Health, explore our interactive list of high quality stocks to get an idea of what else is out there.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.